Skip to main content

DISEÑO DE NANOPARTICULAS INORGANICAS CONJUGADAS:NUEVAS HERRAMIENTAS PARA EL TRATAMIENTO DEL CANCER

MAT2009-14734-C02-02

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2009
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Detoxifying antitumoral drugs via nanoconjugation, The case of gold nanoparticles and cisplatin

  • Comenge, Joan|||0000-0002-9884-1777
  • Sotelo, Carmen
  • Romero, Francisco
  • Gallego Rubio, Oscar|||0000-0001-5665-0967
  • Barnadas i Molins, Agustí|||0000-0002-0429-1349
  • García Caballero Parada, Tomás
  • Domínguez Puente, Fernando|||0000-0002-5003-4335
  • Puntes, Víctor|||0000-0001-8996-9499
Nanoparticles (NPs) have emerged as a potential tool to improve cancer treatment. Among the proposed uses in imaging and therapy, their use as a drug delivery scaffold has been extensively highlighted. However, there are still some controversial points which need a deeper understanding before clinical application can occur. Here the use of gold nanoparticles (AuNPs) to detoxify the antitumoral agent cisplatin, linked to a nanoparticle via a pH-sensitive coordination bond for endosomal release, is presented. The NP conjugate design has important effects on pharmacokinetics, conjugate evolution and biodistribution and results in an absence of observed toxicity. Besides, AuNPs present unique opportunities as drug delivery scaffolds due to their size and surface tunability. Here we show that cisplatin-induced toxicity is clearly reduced without affecting the therapeutic benefits in mice models. The NPs not only act as carriers, but also protect the drug from deactivation by plasma proteins until conjugates are internalized in cells and cisplatin is released. Additionally, the possibility to track the drug (Pt) and vehicle (Au) separately as a function of organ and time enables a better understanding of how nanocarriers are processed by the organism.